12:00 AM
Sep 08, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Prulifloxacin: Completed Phase III enrollment

Optimer completed enrollment in a double-blind, placebo-controlled, international Phase III trial of oral prulifloxacin. The company planned to enroll about...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >